Tyme Technologies to Present at Jefferies Virtual Global Healthcare Conference on November 17-19, 2020
October 13 2020 - 8:00AM
Business Wire
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing
cancer metabolism-based therapies (CMBTs™), announced that its
leadership will present at the Jefferies Virtual Global Healthcare
Conference on November 17-19. In one-on-one sessions, the Company
will present its corporate overview for fiscal year 2021 with a
special focus on multiple growth opportunities driven by advances
in the science of cancer cell metabolism, SM-88 (racemetyrosine)
late-stage trials in pancreatic cancer, SM-88 HopES trial in
ultra-rare metastatic sarcoma, proof-of-concept RESPOnD™ trial
evaluating TYME-19 in COVID-19, and expanding clinical plans for
its cancer-metabolism pipeline candidate SM-88 in prostate, breast
and hematological cancers.
Event: Jefferies Virtual Global Healthcare Conference
Place: Waldorf Hilton, London Presentation Date:
November 17-19, 2020 Format: One-on-one sessions
The presentation will be accessible on the events page under the
investor relations section of Tyme Technologies’ website at
www.tymeinc.com.
About SM-88
SM-88 is an oral investigational modified proprietary tyrosine
derivative that is believed to interrupt the metabolic processes of
cancer cells by breaking down the cells’ key defenses and leading
to cell death through oxidative stress and exposure to the body’s
natural immune system. Clinical trial data have shown that SM-88
has demonstrated encouraging tumor responses across 15 different
cancers, including pancreatic, lung, breast, prostate and sarcoma
cancers with minimal serious grade 3 or higher adverse events.
Learn more.
About TYME-18
TYME-18 is composed of a proprietary surfactant delivery agent
with a specific sulfonic acid component. It is designed for
intra-tumoral administration of difficult to treat tumors and
leverages the acidic tumor microenvironment and signaling pathways
to kill cancer cells. TYME-18 is distinct in composition, but like
SM-88, aims to leverage susceptibilities of a cancer that are
related to its altered metabolism. Initial preclinical data for
TYME-18 in animal tumor models demonstrate rapid and complete tumor
regression, with no reported local or systemic toxicities. TYME-18
continues to be studied as a potential therapy for difficult to
treat tumors that may not be eligible for surgical or other
interventions. Learn more.
About TYME-19
TYME-19 is a potent, well characterized synthetic antiviral bile
acid that is being evaluated as a potential oral therapy for
COVID-19. In preclinical testing, TYME-19 repeatedly prevented
COVID-19 viral replication without attributable cytotoxicity in
treated cells. COVID-19 hijacks a cell’s ability to make proteins
and lipids and divert these processes to make viral proteins and
lipids in order to reproduce. COVID-19 accomplishes this by
inducing stress in the endoplasmic reticulum (ER), where cells
process proteins, which enables the virus to remodel protein and
lipid synthesis. In preclinical testing, TYME-19 has been shown to
counteract these effects, preventing viral replication, by reducing
ER stress. TYME-19 is believed to physically degrade viruses by
solubilizing the protective lipid layer and other structural
components, which prevent a virus from binding to and infecting a
cell.
About TYME-88-Panc Pivotal Trial
The TYME-88-Panc pivotal trial applies the latest advances in
the field of cancer metabolism by evaluating the efficacy and
safety of an oral investigational compound that targets the
metabolic mechanisms of the disease at its source. A prospective,
open label pivotal trial in metastatic pancreatic cancer for
patients who have failed two lines of any prior systemic therapy.
The trial is designed to evaluate the safety and efficacy of SM-88
used with MPS (methoxsalen, phenytoin and sirolimus) in advanced
pancreatic cancer and will measure multiple endpoints, including
overall survival, progression free survival, relevant biomarkers,
quality of life, safety, and overall response rate. Learn more.
About Tyme Technologies
Tyme Technologies, Inc., is an emerging biotechnology company
developing cancer therapeutics that are intended to be broadly
effective across tumor types and have low toxicity profiles. Unlike
targeted therapies that attempt to regulate specific mutations
within cancer, the Company’s therapeutic approach is designed to
take advantage of a cancer cell’s innate metabolic weaknesses to
compromise its defenses, leading to cell death through oxidative
stress and exposure to the body’s natural immune system. For more
information, visit www.tymeinc.com. Follow us on social media:
Follow us on social media: @tyme_Inc, LinkedIn, Instagram, Facebook
and YouTube.
Forward-Looking Statements/Disclosure Notice
In addition to historical information, this press release
contains forward-looking statements under the Private Securities
Litigation Reform Act that involve substantial risks and
uncertainties. The forward-looking statements contained in this
press release are based on management's current expectations, which
are subject to uncertainty, risks and changes in circumstances that
are difficult to predict and many of which are outside of TYME's
control. Factors that could cause actual results to differ
materially from these forward-looking statements include the
Company’s ability to successfully implement its clinical and other
plans, competitive and regulatory developments, and the factors
described in the section captioned “Risk Factors” of TYME’s Annual
Report on Form 10-K filed with the U.S. Securities and Exchange
Commission (“SEC”) on May 22, 2020, as well as subsequent reports
and filings from time to time with the SEC.
The information contained in this press release is as of release
date and TYME assumes no obligation to update forward-looking
statements contained in this release as a result of future events
or developments.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201013005174/en/
For Investor Relations & Media Inquiries: 1-212-461-2315
Investor Relations investorrelations@tymeinc.com
media@tymeinc.com
Tyme Technologies (NASDAQ:TYME)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tyme Technologies (NASDAQ:TYME)
Historical Stock Chart
From Sep 2023 to Sep 2024